Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [517]
News [1432]
Articles [66]
Editorials [2]
Conferences [72]
elearning [5]
Survival analysis of a follow-up phase III study of ipilimumab and dacarbazine...
Dr Michele Maio - University Hospital of Siena, Siena, Italy
Survival analysis of a follow-up phase III study of ipilimumab and dacarbazine in metastatic melanoma ( Dr Michele Maio - University Hospital of Siena, Siena, Italy )
4 Oct 2013
Opportunity for mobile treatment setting for lymphoedema patients
Rachel Iredale - Tenovus, Cardiff, Wales, UK
Opportunity for mobile treatment setting for lymphoedema patients ( Rachel Iredale - Tenovus, Cardiff, Wales, UK )
3 Oct 2013
Analysis of progression free survival versus overall survival in melanoma
Dr Keith Flaherty - Dana-Farber Cancer Institute, Boston, USA
Analysis of progression free survival versus overall survival in melanoma ( Dr Keith Flaherty - Dana-Farber Cancer Institute, Boston, USA )
3 Oct 2013
New antibody drug, MPDL3280A, in non-small cell lung cancer
Prof Jean-Charles Soria - Institut Gustave Roussy, Paris, France
New antibody drug, MPDL3280A, in non-small cell lung cancer ( Prof Jean-Charles Soria - Institut Gustave Roussy, Paris, France )
3 Oct 2013
Meta-analysis of ipilimumab in metastatic or locally advanced, unresectable...
Prof Dirk Schadendorf - Universitätsklinikum Essen, Essen, Germany
Meta-analysis of ipilimumab in metastatic or locally advanced, unresectable melanoma ( Prof Dirk Schadendorf - Universitätsklinikum Essen, Essen, Germany )
3 Oct 2013
Androgen blockade and ipilimumab against castration resistant prostate cancer
Dr Karim Fizazi - Institute Gustave Roussy, Paris, France
Androgen blockade and ipilimumab against castration resistant prostate cancer ( Dr Karim Fizazi - Institute Gustave Roussy, Paris, France )
3 Oct 2013
ecancerNews Highlights from September 2013
Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy
ecancerNews Highlights from September 2013 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )
24 Sep 2013
Developments with PD1 and immunotherapy in melanoma
Prof Lex Eggermont – Institut Gustave Roussy, Villejuif, France
Developments with PD1 and immunotherapy in melanoma ( Prof Lex Eggermont – Institut Gustave Roussy, Villejuif, France )
19 Jul 2013
Establishing immunotherapy as a standard in cancer treatment
Prof Drew Pardoll – Johns Hopkins University School of Medicine, Baltimore, USA
Establishing immunotherapy as a standard in cancer treatment ( Prof Drew Pardoll – Johns Hopkins University School of Medicine, Baltimore, USA )
18 Jul 2013
ECC 2013 Preview: Scientific programme highlights
Prof Vincenzo Valentini and Ian Banks
ECC 2013 Preview: Scientific programme highlights ( Prof Vincenzo Valentini and Ian Banks )
11 Jul 2013
Treatment of melanoma in Latin America
Dr Alessandro Testori - European Institute of Oncology, Milan, Italy
Treatment of melanoma in Latin America ( Dr Alessandro Testori - European Institute of Oncology, Milan, Italy )
9 Jul 2013
Vemurafenib and ipilimumab for metastatic melanoma
Dr Caroline Robert - Institute Gustave Roussy, Paris, France
Vemurafenib and ipilimumab for metastatic melanoma ( Dr Caroline Robert - Institute Gustave Roussy, Paris, France )
14 Jun 2013

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation